Journal of Investigative Dermatology Home

Response to Rigel et al.

      We thank

      Rigel DS, Whitaker JW, Skelsey MK, Peck G, Howell MD, Jansen B. J Invest Dermatol. 2021. (accessed July 23, 2021). Online ahead of print.

      for their interest in our study and the opportunity to clarify our findings.


      PLA (Pigmented Lesion Assay)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      PDF Download and 24 Hours Online Access
      Society Members (SID/ESDR), remember to log in for access.


      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brouha B.
        • Ferris L.K.
        • Skelsey M.K.
        • Peck G.
        • Moy R.
        • Yao Z.
        • et al.
        Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: a large US registry study.
        J Drugs Dermatol. 2020; 19: 257-262
        • Brouha B.
        • Ferris L.K.
        • Skelsey M.K.
        • Peck G.
        • Rock J.
        • Nguyen A.
        • et al.
        Genomic atypia to enrich melanoma positivity in biopsied lesions: gene expression and pathology findings from a large U.S. registry study.
        SKIN J Cutan Med. 2021; 5: 13-18
        • Cohen J.F.
        • Korevaar D.A.
        • Altman D.G.
        • Bruns D.E.
        • Gatsonis C.A.
        • Hooft L.
        • et al.
        STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration.
        BMJ Open. 2016; 6e012799
        • Elmore J.G.
        • Barnhill R.L.
        • Elder D.E.
        • Longton G.M.
        • Pepe M.S.
        • Reisch L.M.
        • et al.
        Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study [published correction appears in BMJ 2017;358:j3798].
        BMJ. 2017; 357: j2813
        • Ensslin C.J.
        • Hibler B.P.
        • Lee E.H.
        • Nehal K.S.
        • Busam K.J.
        • Rossi A.M.
        Atypical melanocytic proliferations: a review of the literature.
        Dermatol Surg. 2018; 44: 159-174
        • Ferris L.K.
        • Gerami P.
        • Skelsey M.K.
        • Peck G.
        • Hren C.
        • Gorman C.
        • et al.
        Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
        Melanoma Res. 2018; 28: 478-482
        • Gerami P.
        • Yao Z.
        • Polsky D.
        • Jansen B.
        • Busam K.
        • Ho J.
        • et al.
        Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.
        J Am Acad Dermatol. 2017; 76: 114-120.e2
        • Hornberger J.
        • Siegel D.M.
        Economic analysis of a noninvasive molecular pathologic assay for pigmented skin lesions.
        JAMA Dermatol. 2018; 154: 1025-1031
      1. Rigel DS, Whitaker JW, Skelsey MK, Peck G, Howell MD, Jansen B. J Invest Dermatol. 2021. (accessed July 23, 2021). Online ahead of print.

        • Vickers A.J.
        • Van Calster B.
        • Steyerberg E.W.
        Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.
        BMJ. 2016; 352: i6
        • Welch H.G.
        • Mazer B.L.
        • Adamson A.S.
        The rapid rise in cutaneous melanoma diagnoses.
        N Engl J Med. 2021; 384: 72-79

      Linked Article

      • Response to Marchetti et al.
        Journal of Investigative DermatologyVol. 142Issue 1
        • Preview
          Recently, Marchetti et al. (2021) used decision-curve analysis and hypothetical models of melanoma biopsy prevalence to retrospectively evaluate the clinical utility of the two Gene Expression Profile Pigmented Lesion Assay (PLA) (DermTech, San Diego, CA). Although the further evaluation of the PLA is appreciated, significant concerns exist regarding material flaws in Marchetti et al. (2021)’s analyses and characterizations. These include (i) incorrectly characterizing the PLA as a test for melanoma diagnosis, (ii) significant challenges within the hypothetical models used and the data input and interpretations employed, and (iii) erroneous assumptions and implications that the social cost of not biopsying a melanoma is equivalent to performing an unneeded biopsy.
        • Full-Text
        • PDF